IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells

Journal of Immunology

Volumn 183, Issue 5, 2009, Pages 3170-3176

  Goodman, Wendy A ^a,b   Levine, Alan D ^a   Massari, Jessica V ^a   Sugiyama, Hideaki ^a,c   McCormick, Thomas S ^a   Cooper, Kevin D ^a,b,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CYTOKINE; GLYCOPROTEIN GP 130; GLYCOPROTEIN P 15095; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; STAT3 PROTEIN; IL6 PROTEIN, HUMAN;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; ADULT; CELL CULTURE; CELL MOTION; DERMIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; PHYSIOLOGY; SECRETION; SIGNAL TRANSDUCTION;

ADULT; CELL MOVEMENT; CELLS, CULTURED; DERMIS; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-6; PSORIASIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 70349241839     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803721     Document Type: Article

References (38)

1. 5 integrin regulate keratinocyte cell cycling: a mechanism for increased fibronectin potentiation of T cell lymphokine-driven keratinocyte hyperproliferation in psoriasis. J. Clin. Invest. 101: 1509-1518.
2. Cooper, K. D., O. Baadsgaard, C. N. Ellis, E. Duell, and J. J. Voorhees. 1990. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J. Invest. Dermatol. 94: 649-656.
3. + perivascular dendritic cells. J. Invest. Dermatol. 96: 333-340.
4. Ellis, C. N., M. S. Fradin, J. M. Messana, M. D. Brown, M. T. Siegel, A. H. Hartley, L. L. Rocher, S. Wheeler, T. A. Hamilton, T. G. Parish, et al. 1991. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N. Engl. J. Med. 324: 277-284.
5. Toichi, E., G. Torres, T. S. McCormick, T. Chang, M. A. Mascelli, C. L. Kauffman, N. Aria, A. B. Gottlieb, D. E. Everitt, B. Frederick, et al. 2006. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177: 4917-4926.
6. Ellis, C. N., and G. G. Krueger. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345: 248-255.
7. Gottlieb, S. L., P. Gilleaudeau, R. Johnson, L. Estes, T. G. Woodworth, A. B. Gottlieb, and J. G. Krueger. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1: 442-447.
8. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16: 81-88.
9. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27.
10. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174: 164-173.
11. Nickoloff, B. J. 2007. Cracking the cytokine code in psoriasis. Nat. Med. 13: 242-244.
12. Somani, A. K., M. F. Yang, K. D. Cooper, and T. S. McCormick. 2007. Cytokines and psoriasis: when cytokines become pathokines. G Ital. Dermatol. Venereol. 142: 679-690.
13. Bata-Csorgo, Z., C. Hammerberg, J. J. Voorhees, and K. D. Cooper. 1995. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture: cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest. 95: 317-327.
14. Ting, K. M., D. Rothaupt, T. S. McCormick, C. Hammerberg, G. Chen, A. C. Gilliam, S. Stevens, L. Culp, and K. D. Cooper. 2000. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J. Invest. Dermatol. 114: 706-711.
15. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
16. Grossman, R. M., J. Krueger, D. Yourish, A. Granelli-Piperno, D. P. Murphy, L. T. May, T. S. Kupper, P. B. Sehgal, and A. B. Gottlieb. 1989. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86: 6367-6371.
17. Neuner, P., A. Urbanski, F. Trautinger, A. Moller, R. Kirnbauer, A. Kapp, E. Schopf, T. Schwarz, and T. A. Luger. 1991. Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J. Invest. Dermatol. 97: 27-33.
18. + subsets. J. Invest. Dermatol. 111: 1072-1078.
19. high regulatory cells in human peripheral blood. J. Immunol. 167: 1245-1253.
20. Das, L., and A. D. Levine. 2008. TGF-β inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction. J. Immunol. 180: 1490-1498.
21. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
22. Parham, C., M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168: 5699-5708.
23. Scheller, J., and S. Rose-John. 2006. Interleukin-6 and its receptor: from bench to bedside. Med. Microbiol. Immunol. 195: 173-183.
24. Kimura, A., T. Naka, and T. Kishimoto. 2007. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA 104: 12099-12104.
25. Sano, S., K. S. Chan, S. Carbajal, J. Clifford, M. Peavey, K. Kiguchi, S. Itami, B. J. Nickoloff, and J. DiGiovanni. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11: 43-49.
26. Szepietowski, J. C., E. Bielicka, P. Nockowski, A. Noworolska, and F. Wasik. 2000. Increased interleukin-7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensity. Clin. Exp. Dermatol. 25: 643-647.
27. Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374: 1-20.
28. H17 cells. Nature 454: 350-352.
29. Zhang, Q., H. Y. Wang, M. Marzec, P. N. Raghunath, T. Nagasawa, and M. A. Wasik. 2005. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc. Natl. Acad. Sci. USA 102: 6948-6953.
30. Yang, J., M. Chatterjee-Kishore, S. M. Staugaitis, H. Nguyen, K. Schlessinger, D. E. Levy, and G. R. Stark. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65: 939-947. (Pubitemid 40216455)
31. + T lymphocytes. J. Immunol. 178: 732-739.
32. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8: 967-974.
33. Chen, Z., and J. J. O'Shea. 2008. Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41: 87-102.
34. Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L. C. Zaba, A. S. Haider, E. P. Bowman, and J. G. Krueger. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128: 1207-1211.
35. Zaba, L. C., I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suarez Farinas, J. Fuentes-Duculan, I. Novitskaya, A. Khatcherian, M. J. Bluth, M. A. Lowes, and J. G. Krueger. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204: 3183-3194.
36. Stummvoll, G. H., R. J. DiPaolo, E. N. Huter, T. S. Davidson, D. Glass, J. M. Ward, and E. M. Shevach. 2008. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J. Immunol. 181: 1908-1916.
37. Serada, S., M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, et al. 2008. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105: 9041-9046.
38. + T cells. J. Exp. Med. 205: 1381-1393.